AMRX:NYE-Amneal Pharmaceuticals, Inc (USD)

COMMON STOCK | Drug Manufacturers—Specialty & Generic | NYE

Last Closing Price

USD 3.98

Change

-0.12 (-2.93)%

Market Cap

USD 0.61B

Volume

1.55M

Average Target Price

USD 5.17 (+29.82%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates in two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers licensed and owned, niche, and mature branded products, as well as Rytary for the treatment of Parkinsons Disease; Zomig for the treatment of migraine headaches; Emverm a chewable tablets for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; and Unithroid for the treatment of hypothyroidism. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It has operations in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is based in Bridgewater, New Jersey.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-11-25 )

Largest Industry Peers for Drug Manufacturers—Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ZTS Zoetis Inc

-0.87 (-0.54%)

USD76.55B 47.93 31.03
TAK Takeda Pharmaceutical Company ..

+0.11 (+0.62%)

USD54.74B 102.71 0.13
CTLT Catalent, Inc

-0.01 (-0.01%)

USD15.59B 64.46 27.60
ELAN Elanco Animal Health Incorpora..

+0.16 (+0.51%)

USD14.92B 144.89 151.28
RDY Dr. Reddy's Laboratories Limit..

-1.20 (-1.83%)

USD11.07B 51.53 0.33
TEVA Teva Pharmaceutical Industries..

-0.11 (-1.12%)

USD10.84B 872.00 16.02
BHC Bausch Health Companies Inc

-0.07 (-0.36%)

USD6.83B N/A 21.21
PRGO Perrigo Company plc

-0.70 (-1.44%)

USD6.64B 24.33 13.97
EBS Emergent BioSolutions Inc

+1.24 (+1.57%)

USD4.20B 26.49 13.06
TARO Taro Pharmaceutical Industries..

-1.25 (-1.79%)

USD2.67B 10.60 4.58

ETFs Containing AMRX

Symbol Name Weight Mer Price(Change) Market Cap
SRLN SPDR Blackstone / GSO Sen.. 0.00 % 0.70 %

+0.01 (+0.02%)

USD1.69B

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers—Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -17.43% 33% F 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -17.43% 33% F 21% F
Trailing 12 Months  
Capital Gain 21.34% 61% D- 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 21.34% 61% D- 82% B-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -30.21% N/A N/A 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -30.21% N/A N/A 1% F
Risk Return Profile  
Volatility (Standard Deviation) 41.27% N/A N/A 11% F
Risk Adjusted Return -73.20% N/A N/A 5% F
Market Capitalization 0.61B 39% F 46% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers—Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 9.20 79% C+ 79% C+
Price/Book Ratio 2.03 44% F 40% F
Price / Cash Flow Ratio 355.00 6% F 1% F
EV/EBITDA 11.24 75% C 58% F
Management Effectiveness  
Return on Equity 2.81% 72% C- 43% F
Return on Invested Capital -12.49% 39% F 8% F
Return on Assets 2.41% 50% F 56% F
Debt to Equity Ratio 1,124.54% 13% F 2% F
Technical Ratios  
Short Ratio 4.90 28% F 21% F
Short Percent 7.45% 31% F 41% F
Beta 1.42 41% F 27% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector